Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Receivables (2019 - 2025)

Purple Biotech has reported Receivables over the past 4 years, most recently at $431000.0 for Q4 2022.

  • Quarterly Receivables rose 123.32% to $431000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $431000.0 through Dec 2022, up 123.32% year-over-year, with the annual reading at $431000.0 for FY2022, 123.32% up from the prior year.
  • Receivables was $431000.0 for Q4 2022 at Purple Biotech, up from $187000.0 in the prior quarter.
  • Over five years, Receivables peaked at $1.5 million in Q4 2019 and troughed at $187000.0 in Q1 2022.
  • The 4-year median for Receivables is $500000.0 (2020), against an average of $516181.8.
  • Year-over-year, Receivables crashed 66.51% in 2020 and then soared 123.32% in 2022.
  • A 4-year view of Receivables shows it stood at $1.5 million in 2019, then crashed by 66.51% to $500000.0 in 2020, then plummeted by 61.4% to $193000.0 in 2021, then soared by 123.32% to $431000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Receivables are $431000.0 (Q4 2022), $187000.0 (Q3 2022), and $187000.0 (Q2 2022).